These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 20861140)
1. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459 [TBL] [Abstract][Full Text] [Related]
3. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature. Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660 [TBL] [Abstract][Full Text] [Related]
4. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313 [TBL] [Abstract][Full Text] [Related]
5. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments. Lincopan N; Mamizuka EM; Carmona-Ribeiro AM J Antimicrob Chemother; 2005 May; 55(5):727-34. PubMed ID: 15761070 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826 [TBL] [Abstract][Full Text] [Related]
7. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611 [TBL] [Abstract][Full Text] [Related]
8. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Sivak O; Gershkovich P; Lin M; Wasan EK; Zhao J; Owen D; Clement JG; Wasan KM Lipids Health Dis; 2011 Aug; 10():135. PubMed ID: 21824435 [TBL] [Abstract][Full Text] [Related]
9. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
10. Study of the toxicity of a new lipid complex formulation of amphotericin B. Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Bartlett K; Wasan KM Int J Pharm; 2012 Oct; 436(1-2):318-23. PubMed ID: 22772485 [TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats. Zhang Z; Diener RM; Lipman JM Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817 [TBL] [Abstract][Full Text] [Related]
13. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565 [TBL] [Abstract][Full Text] [Related]
14. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139 [TBL] [Abstract][Full Text] [Related]
15. High purity amphotericin B. Cleary JD; Chapman SW; Swiatlo E; Kramer R J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178 [TBL] [Abstract][Full Text] [Related]
16. Amphotericin B formulations and drug targeting. Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903 [TBL] [Abstract][Full Text] [Related]
17. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM Eur J Pharm Sci; 2012 Aug; 46(5):323-8. PubMed ID: 22369857 [TBL] [Abstract][Full Text] [Related]
18. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Thornton SJ; Wasan KM Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044 [TBL] [Abstract][Full Text] [Related]
19. Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits. Clemons KV; Sobel RA; Williams PL; Stevens DA Antimicrob Agents Chemother; 2001 Feb; 45(2):612-5. PubMed ID: 11158765 [TBL] [Abstract][Full Text] [Related]
20. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Jain S; Valvi PU; Swarnakar NK; Thanki K Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]